India's Piramal sees $1.5 bln rev from florbetaben
MUMBAI, April 16
MUMBAI, April 16 (Reuters) - Indian drugmaker Piramal Healthcare sees revenue potential of $1.5 billion from its newly acquired florbetaben molecule, which could be used to treat Alzheimer's disease, its chairman, Ajay Piramal, said on Monday.
The company will file for U.S. approval of the treatment in late 2012, Piramal added.
Piramal agreed to buy a research and development portfolio from Germany's Bayer AG in a deal that gives the Indian drugmaker commercial and development rights to florbetaben. (Reporting by Kaustubh Kulkarni; Editing by Aradhana Aravindan)
- Air strike kills 15 civilians in Yemen by mistake: officials
- North Korea executes leader's powerful uncle in rare public purge |
- Insight: In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
- Storm to cloak Midwest to Northeast in snow, freezing rain
- Twitter backtracks on block feature after users revolt |